Not a standalone service — a front-end tool that strengthens the GLP system. Through our deep partnership with SinoGenoMax (National Human Genome Center, North), multi-omics profiling surfaces the right targets and biomarkers up front, so the GLP phase answers focused questions under ICH guidelines.
SinoGenoMax (National Human Genome Center, North) is part of the platform's drug-development chain. Multi-omic profiling is coordinated by the platform and delivered as a front-end enhancement to the GLP programme.
Through our deep partnership with SinoGenoMax (National Human Genome Center, North), multi-omics — transcriptomics, metagenomics, methylation and liquid-biopsy profiling — sharpens target and biomarker selection up front. Better-defined hypotheses enter the GLP phase, so fewer studies are wasted on the wrong question.
The platform's multi-omics capability is delivered through a deep partnership with SinoGenoMax, the operating entity of the National Human Genome Center, North — a national-level genomics research infrastructure.
SinoGenoMax operates large-scale sequencing infrastructure, multi-omic analysis pipelines, and biobank resources at the national level. Through this partnership, the platform integrates transcriptomics, metagenomics, methylation profiling, and liquid-biopsy capabilities into the drug-development chain — all coordinated under one Seno.Bio contract.
You contract with Seno.Bio: one plan, one contract, one accountable partner. The multi-omics work is coordinated by the platform and delivered as part of the GLP front-end enhancement layer.